Category: by subject

Former rising star found guilty of misconduct issues 2nd retraction

A once-lauded researcher in the field of infectious disease — who has since been found guilty of misconduct — has retracted a second paper.

Last year, the University of Dundee in Scotland investigated and ultimately concluded that Robert Ryan — whose work focused on infections that can be deadly in people with lung diseases such as cystic fibrosis — had committed “serious research misconduct,” affecting multiple publications. After appealing the decision, Ryan resigned.

We covered his first retraction earlier this month, which cited multiple instances of image duplication. Now Ryan has retracted his second paper, published in 2011 in Journal of Bacteriology, also due to image problems.

Here’s the retraction notice: Continue reading Former rising star found guilty of misconduct issues 2nd retraction

Harvard teaching hospital to pay $10 million to settle research misconduct allegations

Piero Anversa

Brigham and Women’s Hospital and its parent healthcare network have agreed to pay $10 million to the U.S. government to resolve allegations it fraudulently obtained federal funding.

The case, which involves three former Harvard stem cell researchers, dates back several years. In 2014, Circulation retracted a paper by Piero Anversa, Annarosa Leri, and Jan Kajstura, among others, amidst a university investigation into misconduct allegations. Anversa and Leri — whose lab was described as filled with “fear” by one former research fellow — later sued the hospital for notifying journals of that investigation. They lost.

In the agreement announced today by the Department of Justice (DOJ), Partners Healthcare and Brigham and Women’s Hospital have agreed to pay the government $10 million to settle allegations that the researchers fraudulently obtained funding from the National Institutes of Health:

Continue reading Harvard teaching hospital to pay $10 million to settle research misconduct allegations

Public health journal’s editorial board tells publisher they have “grave concerns” over new editor

First, an occupational health journal appointed a new editor with industry ties without consulting the editorial board. Then, with no explanation, it withdrew a paper by the previous editor that was critical of corporate-sponsored research — again, without consulting the editorial board.

At that point, they’d had enough.

Yesterday, the editorial board of the International Journal of Occupational and Environmental Health sent a letter to the publisher, Taylor & Francis, expressing their “grave concerns” over the future of the journal, and its recent actions.

As part of the letter — signed by 30 past and present editorial members and the founding editor — they write:

Continue reading Public health journal’s editorial board tells publisher they have “grave concerns” over new editor

A university asked for numerous retractions. Eight months later, three journals have done nothing.

Anil Jaiswal

When journals learn papers are problematic, how long does it take them to act?

We recently had a chance to find out as part of our continuing coverage of the case of Anil Jaiswal at the University of Maryland, who’s retracted 15 papers (including two new ones we recently identified), and has transitioned out of cancer research. Here’s what happened.

As part of a public records request related to the investigation, we received letters that the University of Maryland sent to 11 journals regarding 26 “compromised” papers co-authored by Jaiswal, four of which had been retracted by the time of the letter. The letters were dated between August and September 2016 (and one in February) — although, in some cases, the journals told us they received the letter later. Since that date, three journals have retracted nine papers and corrected another, waiting between four and six months to take action. One journal published an editorial note of concern within approximately two months after the university letter.

And six journals have not taken any public action.

Continue reading A university asked for numerous retractions. Eight months later, three journals have done nothing.

A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

Last year, a researcher cast doubt on a bone scientist’s clinical trials, suggesting some of the findings may not be legitimate. So what’s happened since?

Since 2015, journals have retracted 14 papers by bone researcher Yoshihiro Sato, based at Mitate Hospital in Japan, for issues ranging from self-plagiarism, to problems with data, to including co-authors without their consent. (We covered the latest two retractions this week.) Last year’s analysis identified patterns in more than 30 of Sato’s clinical trials that suggest systematic problems with the results. (Sato has defended his research.)

With doubts cast on Sato’s body of work, we contacted the journals that have published his papers involving human trials, to see if any taken another look at Sato’s work; several responded. While most believe there is little reason to take further action at this time, some told us they are investigating.
Continue reading A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

Harvard diabetes researcher retracts third paper

A prominent diabetes researcher based at Harvard Medical School has retracted a third paper, citing manipulation of multiple figures.

Late last year, Carl Ronald Kahn—also chief academic officer at Joslin Diabetes Center—retracted two papers for similar reasons. In November, Kahn pulled a 2005 paper from The Journal of Clinical Investigation (JCI) and a month later, he retracted a 2003 paper from The Journal of Biological Chemistry (JBC), both times citing duplications that the authors said were introduced while assembling the figures.

Last month, Kahn retracted his third paper, also published in JBC in 2003, because the authors omitted data when constructing the images. Still, the authors remain confident in their findings, given that data from other labs “have confirmed and extended the conclusions of the manuscript.”

Here’s the retraction notice: Continue reading Harvard diabetes researcher retracts third paper

Plant biologist earns string of retractions, bringing total to 9

A pair of plant biologists has lost a string of papers over concerns about image manipulation. One author has added eight new retractions to his CV; the other has added five.

Last summer, a journal retracted another paper by the pair, also citing suspicions of image manipulation. The latest batch of retractions — issued by seven different journals — includes some papers that have been questioned on PubPeer.

Dibyendu Talukdar, listed at the University of Calcutta in West Bengal, India, is the sole author on three retracted papers. He shares five new retractions with Tulika Talukdar listed at the University of North Bengal. That brings their totals to nine and six, respectively. (We’re not sure if the Drs. Talukdar are related).

We’ll start with the papers they share: Continue reading Plant biologist earns string of retractions, bringing total to 9

Chemist wins injunction against university trying to revoke her degree

A scientist has won an injunction against the University of Texas at Austin, which was deciding whether or not to revoke her PhD.

We’ve been covering the case of Suvi Orr, a chemist now based at Pfizer who earned a PhD in 2008, for a few years. During that time, UT has tried to revoke her degree twice, after the paper that made up part of her dissertation was retracted in 2012 — for allegedly containing falsified data, according to the school. The university revoked her degree in 2014, then reinstated it after she sued.

Last year, the school tried to revoke it again, prompting Orr to sue for a second time — and ask for more than $95,000 in legal fees and expenses.

In a decision released April 20, a Texas Court of Appeals has upheld Orr’s request for an injunction against UT, preventing it from deciding whether to revoke her degree. Specifically, Orr asked that UT not be allowed to make a decision until the court has weighed in on a separate appeal, in which Orr argues the university doesn’t have the right to revoke her degree.

According to her lawyer, David Sergi:

Continue reading Chemist wins injunction against university trying to revoke her degree

A new record: Major publisher retracting more than 100 studies from cancer journal over fake peer reviews

Springer is retracting 107 papers from one journal after discovering they had been accepted with fake peer reviews. Yes, 107.

To submit a fake review, someone (often the author of a paper) either makes up an outside expert to review the paper, or suggests a real researcher — and in both cases, provides a fake email address that comes back to someone who will invariably give the paper a glowing review. In this case, Springer, the publisher of Tumor Biology through 2016, told us that an investigation produced “clear evidence” the reviews were submitted under the names of real researchers with faked emails. Some of the authors may have used a third-party editing service, which may have supplied the reviews. The journal is now published by SAGE.

The retractions follow another sweep by the publisher last year, when Tumor Biology retracted 25 papers for compromised review and other issues, mostly authored by researchers based in Iran. With the latest bunch of retractions, the journal has now retracted the most papers of any other journal indexed by Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters. In 2015, its impact factor — 2.9 — ranked it 104th out of 213 oncology journals.

Here’s more from Springer’s official statement, out today:

Continue reading A new record: Major publisher retracting more than 100 studies from cancer journal over fake peer reviews

“Think of the unthinkable:” JAMA retraction prompts author to urge others to share data

A few months ago, a researcher told Evelien Oostdijk there might be a problem with a 2014 JAMA study she had co-authored.

The study had compared two methods of preventing infection in the intensive care unit (ICU). But a separate analysis had produced different results.

Oostdijk, from the University Medical Center Utrecht in The Netherlands, immediately got to work to try to figure out what was going on. And she soon discovered the problem: The coding for the two interventions had been reversed at one of the 16 ICUs. This switch had “a major impact on the study outcome,” last author Marc Bonten, also from the University Medical Center Utrecht, wrote in a blog post about the experience yesterday, because it occurred at “one of the largest participating ICUs.”

When Oostdijk and a researcher not involved in the study analyzed the data again, they discovered a notable difference between the revised and original findings: The new analysis revealed that one of the interventions had a small but significant survival benefit over the other.

Oostdijk and Bonten, who supervised the re-analysis, notified their colleagues of the revised study outcomes and contacted the journal requesting a retraction and replacement, which was published yesterday in JAMA.

According to the notice of retraction and replacement:

Continue reading “Think of the unthinkable:” JAMA retraction prompts author to urge others to share data